Careers | Find us | Contact us
2025-01-16T14:21:41+00:001 December 2024|
Based originally upon the research of the human microbiome carried out at the Wellcome Sanger Institute, Microbiotica was spun out as a microbiome therapeutics company in 2016. Today, Microbiotica is advancing steadily towards introducing transformational microbiome-based therapeutics and biomarkers in areas of high medical need, with first clinical trials – underpinned by a landmark £50m investment during 2022 – starting soon.
2025-06-24T16:46:17+01:0016 January 2024|
Based on pioneering research from the Wellcome Sanger Institute and the UK NHS, Congenica has a global footprint supporting leading international laboratories, academic medical centres, and biopharmaceutical companies and is the exclusive Clinical Decision Support partner for the NHS Genomic Medicine Service.
2025-06-24T16:44:53+01:0012 January 2024|
Kymab was a therapeutic antibody company based in Cambridge, UK, developing novel solutions in drug and vaccine development. Using its unique technology with roots in the laboratories of the Wellcome Sanger Institute, the company developed broad diversity, high-quality human antibodies. Kymab's therapeutics were designed to modulate the immune system to overcome cancer immune tolerance and to treat autoimmune diseases.
2024-07-05T10:41:23+01:0013 November 2023|
To celebrate Global Entrepreneurship Week, Dr Joanna Mills tells us what Entrepreneurship looks like at the Sanger Institute.
2024-10-21T10:19:02+01:002 December 2021|
Much of our research has the potential to positively impact people's lives around the world. And who better to deliver this than the scientists themselves?
Wellcome Genome Campus,
Hinxton, Cambridgeshire,
CB10 1SA. UK
+44 (0)1223 834244
Wellcome Genome Campus,
Hinxton, Cambridgeshire, CB10 1SA. UK
+44 (0)1223 834244
